<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41730">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01732224</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HBV Reactivation-01</org_study_id>
    <nct_id>NCT01732224</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B</brief_title>
  <official_title>A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relevant data will be prospectively collected included patient demographics, clinical,
      all laboratory variables including virological tests, genotyping by direct sequencing,
      abdominal ultrasound, and upper gastrointestinal (GI) endoscopy. Trans jugular liver biopsy
      (TJLB) and hepatic venous pressure gradient (HVPG) will be done in patients when it was not
      evident whether the underlying liver disease was chronic based on clinical, biochemical,
      radiological investigations, and upper GI endoscopy. Severity of the liver disease will be
      assessed by Child-Turcotte Pugh score (CTP) and model for end stage liver disease (MELD)
      score.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>1 and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction in HBV DNA.</measure>
    <time_frame>7 days, 15 days, 1 month and 3 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug(s) related adverse effects/ side effects</measure>
    <time_frame>1 and 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in CTP and MELD scores</measure>
    <time_frame>1 and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alteration of  renal functions</measure>
    <time_frame>1 and 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Spontaneous Reactivation of Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Tenofovir + Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir (300 mg/day) plus telbivudine (600 mg/day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In tenofovir arm subjects will receive tenofovir (300 mg) once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + Telbivudine</intervention_name>
    <description>Tenofovir (300 mg/day) plus telbivudine (600 mg/day).</description>
    <arm_group_label>Tenofovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>In tenofovir arm subjects will receive tenofovir (300 mg) once daily.</description>
    <arm_group_label>Tenofovir + Telbivudine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reactivation of CHB characterized by a rise in ALT level &gt;5 times upper limit of
             normal along with HBV DNA level &gt;10^5 copies/ mL (&gt; 1.8 X 10^4 IU/mL).

        Exclusion Criteria:

          1. Superinfection with other viruses (hepatitis E, A, D, or C)

          2. other causes of chronic liver failure

          3. coexistent hepatocellular carcinoma (HCC)

          4. portal vein thrombosis

          5. coexistent renal impairment

          6. pregnancy

          7. coinfection with human immunodeficiency virus (HIV)

          8. patients who had received a previous course of any antiviral, immunomodulator or
             cytotoxic/immunosuppressive therapy for chronic hepatitis or other illness within at
             least the preceding 12 months.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiv Kumar Sarin, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences (ILBS).</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr Ankur Jindal, MD</last_name>
    <phone>9582670984</phone>
    <email>ankur.jindal3@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences (ILBS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ankur Jindal, MD</last_name>
      <phone>+91-9582670984</phone>
      <email>ankur.jindal3@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dr Ankit Bhardwaj</last_name>
      <phone>011-46300000</phone>
      <phone_ext>1032</phone_ext>
      <email>bhardwaj.ankit3@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shiv Kumar Sarin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>May 7, 2014</lastchanged_date>
  <firstreceived_date>November 19, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Tenofovir disoproxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
